Graph AI raises $13.3M in Series A funding

Graph AI, a pharmaceutical-focused technology startup, has secured $13.3 million in Series A funding to expand its operations and accelerate product development. The investment round, led by Insight Partners and including participation from Bessemer Venture Partners, will enable Graph AI to strengthen its presence in the US and Europe markets.

Founded in 2024 by former employees from tech giants like Google, Wipro, Infosys, LTI, and ServiceNow, Graph AI has developed an AI-powered platform aimed at revolutionizing pharmacovigilance and patient safety. Traditionally, pharmacovigilance has relied on adding more manpower and legacy systems to cope with increasing case volumes.

However, Graph AI argues that AI can change this approach by providing an intelligent system that handles operational complexity while maintaining traceability, accountability, and human oversight.

Graph AI's platform integrates AI with deterministic controls, validation layers, and end-to-end audit trails, all tailored to comply with regulatory requirements and evolving expectations for AI in medicines development and patient safety. In live deployments, the company claims its platform has cut case processing turnaround time from over 3 hours to less than 10 minutes, achieving cost reductions of up to 66%.

Graph AI's platform has already been adopted by pharmaceutical and biotech customers across North America and other markets. The company has also secured design partnerships for its modules ahead of time. Richard Matus, Principal at Insight Partners, highlighted the importance of ensuring patient safety, stating that few pharma companies want to manage the integration of disparate tools for this purpose.

Meanwhile, software and service providers in the industry have yet to fully leverage AI to enhance accuracy and value for pharma customers.